Description: Rakovina Therapeutics, Inc., formerly Vincero Capital Corp., is a Canada-based company, which is engaged in developing cancer treatments based on DNA-damage response technologies. The Company’s lead product candidate is kt-2000 Next Generation PARP-inhibitors. Its pipeline includes kt-3000 Dual Action DDR-inhibitors and kt-4000 DNA Damaging DDR-inhibitors. Its kt-2000 series is a patented class of highly potent, oral inhibitors of poly (ADP-ribose) polymerase (PARP). Its kt-3000 drug candidates selectively inhibit secondary DDR pathways associated with treatment resistance and PARP. kt-4000 drug candidates release a potent DNA-damaging agent, while also inhibiting DDR to selectively kill cancer cells.
Home Page: www.rakovinatherapeutics.com
RKV Technical Analysis
1008 Beach Avenue
Vancouver,
BC
V6E 1T7
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Jeffrey A. Bacha B.Sc., M.B.A. | Exec. Chairman |
| Dr. Mads Daugaard | Pres & Chief Scientific Officer |
| Mr. David Hyman CA, CBV | CFO & Corp. Sec. |
| Dr. John Langlands Ph.D. | Chief Operating Officer |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7935 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |